Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients With Dry Eye Disease
9/20/2013 10:13:27 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the 7th International Conference on Tear Film & the Ocular Surface (TFOS) in Taormina, Sicily. Eleven Biotherapeutics researchers presented data that demonstrated positive Phase 1b/2a clinical results with EBI-005 and its dual action on treating both the signs and symptoms of dry eye disease (DED). Based on these results, Eleven Biotherapeutics will advance EBI-005 into a pivotal efficacy and safety, multi-center clinical trial in patients with DED.
Help employers find you! Check out all the jobs and post your resume.
comments powered by